Generic Medicine Info
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Special Precautions
Patients inadequately hydrated or at risk of dehydration; immunocompromised patients. Concomitant use with nephrotoxic agents. Renal and hepatic impairment. Elderly. Pregnancy and lactation. Patient Counselling This drug does not reduce your risk of passing genital herpes through sexual contact, if symptoms are present, avoid sexual intercourse or use safer sex practices. Monitoring Parameters Monitor LFTs, CBC, BUN, serum creatinine and urinalysis regularly during treatment. Assess for signs of CNS changes.
Adverse Reactions
Significant: Acute renal failure, CNS effects (e.g. agitation, hallucination, confusion, delirium, seizures, encephalopathy). Blood and lymphatic system disorders: Thrombocytopenia, leucopenia. Gastrointestinal disorders: Nausea, abdominal pain, vomiting, diarrhoea. General disorders and administration site conditions: Fatigue, ataxia, fever. Immune system disorders: Urticaria. Rarely, anaphylaxis, angioedema. Investigations: Elevated liver enzymes. Metabolism and nutrition disorders: Dehydration. Musculoskeletal and connective tissue disorders: Arthralgia. Nervous system disorders: Headache, dizziness, decreased consciousness, tremor. Psychiatric disorders: Dysarthria. Renal and urinary disorders: Renal pain, haematuria. Reproductive system and breast disorders: Dysmenorrhoea. Respiratory, thoracic and mediastinal disorders: Nasopharyngitis, dyspnoea. Skin and subcutaneous tissue disorders: Rashes, pruritus, photosensitivity.
Potentially Fatal: In patients with advanced HIV infection receiving high doses (8,000 mg daily) for prolonged period: Thrombotic thrombocytopenic purpura, haemolytic uremic syndrome.
Drug Interactions
Increased risk of renal impairment with nephrotoxic drugs (e.g. aminoglycosides, organoplatinum compounds, iodinated contrast media, methotrexate, pentamidine, foscarnet, ciclosporin, tacrolimus). Probenecid and cimetidine may reduce renal clearance of aciclovir.
CIMS Class
ATC Classification
J05AB11 - valaciclovir ; Belongs to the class of nucleosides and nucleotides excluding reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Disclaimer: This information is independently developed by CIMS based on valaciclovir from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in